

Investigating the effect of bintrafusp alfa, a bifunctional fusion protein designed for colocalized, simultaneous inhibition of the TGF- β and PD-L1 pathways, in multiple cancer types.

Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

INTR@PID[™] CERVICAL 046¹ Now Enrolling



ADVANCED
CERVICAL CANCER




PHASE
1



COMBINATION
THERAPY

INTR@PID CERVICAL 046 (NCT04551950) is a phase 1, open-label study evaluating bintrafusp alfa with other anticancer therapies for the treatment of patients with locally advanced or persistent, recurrent, or metastatic cervical cancer.

Study design | Global



Key inclusion criteria[§]

- Participants must have an ECOG PS of 0 or 1
- Participants in cohort 1 must have persistent, recurrent, or metastatic cervical cancer and not have received prior systemic chemotherapy that was not given as part of concurrent chemoradiation
- Participants in cohort 2 must have FIGO 2018 stage IB2 to IVA cervical cancer and must not have received prior chemotherapy or radiation therapy for cervical cancer


Key exclusion criteria[§]

- Participants must not have received prior cancer treatment with any immunotherapy, checkpoint inhibitor, or immune-modulating monoclonal antibody

*For 2 years or until confirmed disease progression, death, unacceptable toxicity, or study withdrawal. †Chemotherapy consists of cisplatin/carboplatin + paclitaxel. ‡Concurrent chemoradiation consists of radiation therapy + cisplatin. §For a full list of inclusion and exclusion criteria, please visit www.clinicaltrials.gov.

DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; FIGO, International Federation of Gynecology and Obstetrics; PD-L1, programmed death ligand 1; TGF- β , transforming growth factor β .

Reference: 1. ClinicalTrials.gov. Bintrafusp alfa combination therapy in participants with cervical cancer (INTR@PID 046). <https://clinicaltrials.gov/ct2/show/NCT04551950>. Accessed February 4, 2021.



For more information, visit
www.intrapidclinicaltrials.com
www.clinicaltrials.gov